FDA Peptide Reclassification 2026: Which 12 Peptides Are Being Restored Under RFK Jr.

What Happened: The Short Version

On April 15, 2026, the FDA announced it would begin the process of removing 12 peptides from its Category 2 "difficult to compound" list — effectively reversing a sweeping 2023 ban that had shut down compounding pharmacy access to some of the most widely used therapeutic peptides in the country.

This decision came after intense political pressure from HHS Secretary Robert F. Kennedy Jr. and the broader Make America Healthy Again (MAHA) movement, which has championed peptide therapy access as a core health-freedom issue.

The 12 peptides will now undergo formal review by the Pharmacy Compounding Advisory Committee (PCAC), with the first batch scheduled for a public hearing on July 23–24, 2026.

Background: The 2023 Category 2 Peptide Ban

In late 2023, the FDA moved 19 peptides from Category 1 (eligible for compounding) to Category 2 (effectively banned from compounding pharmacies). The agency cited concerns over safety data, chemical stability, and the lack of adequate characterization for bulk compounding.

The original 19 peptides placed on Category 2 included:

The ban drew immediate backlash from compounding pharmacies, functional medicine practitioners, and patient advocacy groups. Many patients who had been using peptides like BPC-157 and TB-500 for injury recovery, gut healing, and chronic inflammation found themselves suddenly without access to their treatments.

RFK Jr. and the MAHA Movement's Role

Since taking office as HHS Secretary, Robert F. Kennedy Jr. has made peptide access one of his signature health policy priorities. Kennedy has personally advocated for the reclassification of banned peptides, framing the issue as a matter of health freedom and patient autonomy.

Key actions from the Kennedy-led HHS include:

• Direct engagement with FDA leadership — Kennedy reportedly met with FDA officials multiple times to request a formal review of the Category 2 list.
• Public statements — In March 2026, Kennedy publicly stated that the peptide bans were "based on insufficient evidence" and that "Americans deserve access to compounds that have helped them."
• MAHA coalition pressure — The broader Make America Healthy Again movement organized public comment campaigns targeting the FDA's compounding docket.
• Congressional allies — Several members of Congress sent letters to the FDA supporting peptide reclassification, citing constituent complaints about lost access.

Critics, including some FDA career scientists and groups like the American Medical Association, have argued that the reclassification is politically motivated and that these peptides lack the safety and efficacy data normally required for compounding approval. A ProPublica investigation noted concerns about adverse events linked to compounded peptides, including hospitalizations.

The 12 Peptides Being Reclassified

The FDA's April 15, 2026 announcement specifically identified 12 peptides for removal from Category 2 and formal PCAC review. These 12 are being evaluated in two waves:

Wave 1: PCAC Hearing — July 23–24, 2026

The first 7 peptides will be reviewed at a public PCAC meeting at the FDA campus in Silver Spring, Maryland:

Wave 2: Estimated Review by February 2027

The remaining 5 peptides are scheduled for PCAC review in a second wave:

• LL-37 — Cathelicidin antimicrobial peptide. Broad-spectrum antimicrobial and immune modulator.
• GHK-Cu (Injectable) — Copper peptide complex. Researched for wound healing, collagen synthesis, and skin rejuvenation.
• DiHexa — Angiotensin IV analog. One of the most potent cognitive enhancers ever studied, with research showing dramatic improvements in synaptic connectivity.
• Melanotan II — Melanocortin receptor agonist. Researched for tanning, sexual dysfunction, and appetite modulation.
• PEG-MGF — PEGylated Mechano Growth Factor. Studied for muscle recovery and growth enhancement.

Peptides That Remain Banned (Category 2)

Seven peptides from the original 2023 list were not included in the reclassification announcement and remain on Category 2. Most of these are growth hormone secretagogues:

• Ipamorelin — Selective GH secretagogue
• GHRP-2 — Growth Hormone Releasing Peptide-2
• GHRP-6 — Growth Hormone Releasing Peptide-6
• CJC-1295 — Growth Hormone Releasing Hormone analog
• Kisspeptin-10 — Reproductive hormone regulator
• Selank — Anxiolytic peptide
• Thymosin Alpha-1 — Immune modulator

The exclusion of GH secretagogues likely reflects the FDA's concern about their overlap with regulated growth hormone therapies. Ipamorelin, CJC-1295, GHRP-2, and GHRP-6 all stimulate growth hormone release, which is a more tightly controlled regulatory space.

The exclusion of Selank and Thymosin Alpha-1 is less clear-cut and may be revisited in future rulemaking cycles.

What Happens at the PCAC Meeting

The Pharmacy Compounding Advisory Committee (PCAC) is an independent advisory panel that makes recommendations to the FDA on compounding issues. Here's what to expect at the July 23–24, 2026 hearing:

1. FDA staff presentation — Agency scientists will present their review of available safety, efficacy, and characterization data for each peptide.
2. Public comment period — Patients, physicians, pharmacists, and industry representatives can submit written or oral testimony.
3. Committee deliberation — PCAC members will discuss the evidence and vote on whether each peptide should be reclassified to Category 1.
4. Recommendation — The committee issues a recommendation, which the FDA typically (but is not required to) follow.

The PCAC meeting details are published on the FDA website. Public comments can be submitted through the Federal Register docket.

What This Means for Patients and Providers

If the PCAC review results in reclassification to Category 1, compounding pharmacies will once again be able to compound these peptides for patients with valid prescriptions. Here's the practical impact:

For Patients

• Restored access — Patients who lost access to BPC-157, TB-500, and other therapeutic peptides in 2023 may regain legal access through compounding pharmacies.
• Timeline — Even with a favorable PCAC vote, formal reclassification could take several months. Patients should not expect immediate availability.
• Quality assurance — Compounded peptides from licensed 503A and 503B pharmacies will continue to be subject to state and federal oversight.

For Compounding Pharmacies

• Business recovery — The 2023 ban devastated many pharmacies that had built their practice around peptide compounding. Reclassification would allow them to resume operations.
• New compliance requirements — The PCAC may recommend additional quality controls, testing standards, or labeling requirements as conditions of reclassification.

For the Broader Market

The reclassification has implications beyond just compounding. Companies like Hims & Hers Health (HIMS) — which has built a telehealth peptide business — saw significant stock movement following the FDA announcement. The broader health and wellness market is watching closely, as peptide therapy continues to grow in mainstream acceptance.

Full Timeline of Events

Frequently Asked Questions

Learn More About These Peptides

PeptideKnow maintains comprehensive profiles for each peptide mentioned in this article, including detailed mechanisms of action, dosage protocols, stacking guides, and research references:

For a broader understanding of peptides, start with our Beginner's Guide to Peptides or explore our full peptide database.